Anixa Biosciences, Inc. filings document regulatory disclosures for a cancer-focused biotechnology company developing vaccine and CAR-T therapy programs. Recent Form 8-K reports include Regulation FD disclosures on the company's ovarian cancer CAR-T program, lira-cel, and its investigational breast cancer vaccine, including related press releases and scientific-presentation exhibits.
The company's proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, common-stock voting results, and other governance matters. These filings provide the formal record for Anixa's public-company reporting around clinical-program updates, stockholder actions, and corporate oversight.
Anixa Biosciences Inc (ANIX) reported that Amit Kumar, its Chief Executive Officer and a director, purchased 5,000 shares of common stock at $3.17 per share on October 30, 2026. His directly held position after the purchase was 685,000 shares. The transaction is described as a purchase in the open market or a private transaction.
Anixa Biosciences Inc (ANIX) director Lewis H. Titterton Jr. purchased 8,000 common shares directly on October 23, 2026, at $2.98 per share. His reported direct holdings after the purchase were 1,054,003 shares. No Rule 10b5-1 plan is reported.
Anixa Biosciences Inc Chief Executive Officer Amit Kumar purchased 8,000 shares of Common Stock on October 22, 2026, at $2.72 per share. The shares were held directly, and his reported direct ownership after the purchase was 680,000 shares. No Rule 10b5-1 plan is reported for the transaction; the purchase count is separate from his post-transaction holding.
Anixa Biosciences Inc (ANIX) President, COO, & CFO Michael Catelani purchased 5,500 shares of common stock at $2.84 per share on September 30, 2026. The shares were held directly, and his reported position after the purchase was 50,000 shares. The transaction is listed as a non-derivative purchase, and no Rule 10b5-1 plan is reported.
Anixa Biosciences Inc Chief Executive Officer Amit Kumar directly purchased 7,000 common shares on September 24, 2026, at $2.78 per share. The transaction is described as an open-market or private-transaction purchase, and no Rule 10b5-1 plan is reported. Kumar held 672,000 shares directly after the purchase.
Anixa Biosciences Inc director Arnold M. Baskies purchased 5,000 shares of common stock on September 24, 2026, at $2.76 per share. The transaction is described as a purchase in the open market or a private transaction, and the shares were directly owned. Baskies directly held 140,572 shares after the purchase. No Rule 10b5-1 plan is reported.
Anixa Biosciences Inc (ANIX) director Lewis H. Titterton Jr. purchased 49,036 shares of Common Stock on September 23, 2026, at $2.69 per share. The shares were held directly, and his reported direct holdings after the purchase were 1,046,003 shares. No Rule 10b5-1 plan is reported.
Anixa Biosciences Inc (ANIX) director and Chief Executive Officer Amit Kumar purchased additional Common Stock in the company. On September 10, 2026, he bought 3,000 shares in an open-market or private transaction at $2.75 per share, bringing his directly held stake to 665,000 shares. No Rule 10b5-1 trading plan is reported for this transaction.
Anixa Biosciences Inc (ANIX) director Lewis H. Titterton Jr. reported purchasing 10,000 shares of common stock on September 10, 2026 in an open-market or private transaction at $2.73 per share. Following this purchase, he directly holds 996,967 shares of Anixa Biosciences common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Anixa Biosciences Inc (ANIX) director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock on September 10, 2026 at $2.76 per share in an open-market or private transaction. Following this purchase, he directly owns 662,000 shares of Anixa common stock. No Rule 10b5-1 trading plan is reported for this transaction.